Risk factors for drug-related non-infectious pneumonia: insights from the FDA adverse event reporting system (FAERS).

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Peize Meng, Yi Zhang, Qingnan Zhao, Hang Zhang, Zheng Ruan
{"title":"Risk factors for drug-related non-infectious pneumonia: insights from the FDA adverse event reporting system (FAERS).","authors":"Peize Meng, Yi Zhang, Qingnan Zhao, Hang Zhang, Zheng Ruan","doi":"10.1080/14740338.2025.2500716","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Non-infectious pneumonitis (NIP) is a severe adverse drug reaction. To better understand drug-induced NIP, improve patient safety, and inform clinical decision-making, this study aims to utilize the FDA Adverse Event Reporting System (FAERS) database to evaluate the association between medications and NIP, identify potential risk factors, and offer clinical alerts.</p><p><strong>Research design and methods: </strong>We reviewed the FAERS database from the 2004 through the second quarter of 2024. Using 'NIP' as the search term, we sorted, counted, and analyzed cases by generic drug name and trends of reports related to NIP submitted to FAERS database. We employed four statistical methods to identify drugs associated with the NIP.</p><p><strong>Results: </strong>From 21,433,114 reported drug adverse events (AEs), 9,224 cases were classified as NIP. Our analysis identified 20 drugs associated with NIP, with the main categories being antineoplastic agents, antibiotics and immunosuppressants. Daptomycin, methotrexate, and tacrolimus had the highest NIP-related deaths. Trends in AEs reporting indicate that the drugs showing the fastest increase in NIP reports are daptomycin, methotrexate, sertraline, and amiodarone.</p><p><strong>Conclusion: </strong>These findings could assist clinicians in the early identification of drug-related NIP and provide valuable insights for future research into the mechanisms underlying drug-related NIP.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-12"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2025.2500716","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Non-infectious pneumonitis (NIP) is a severe adverse drug reaction. To better understand drug-induced NIP, improve patient safety, and inform clinical decision-making, this study aims to utilize the FDA Adverse Event Reporting System (FAERS) database to evaluate the association between medications and NIP, identify potential risk factors, and offer clinical alerts.

Research design and methods: We reviewed the FAERS database from the 2004 through the second quarter of 2024. Using 'NIP' as the search term, we sorted, counted, and analyzed cases by generic drug name and trends of reports related to NIP submitted to FAERS database. We employed four statistical methods to identify drugs associated with the NIP.

Results: From 21,433,114 reported drug adverse events (AEs), 9,224 cases were classified as NIP. Our analysis identified 20 drugs associated with NIP, with the main categories being antineoplastic agents, antibiotics and immunosuppressants. Daptomycin, methotrexate, and tacrolimus had the highest NIP-related deaths. Trends in AEs reporting indicate that the drugs showing the fastest increase in NIP reports are daptomycin, methotrexate, sertraline, and amiodarone.

Conclusion: These findings could assist clinicians in the early identification of drug-related NIP and provide valuable insights for future research into the mechanisms underlying drug-related NIP.

药物相关非感染性肺炎的危险因素:来自FDA不良事件报告系统(FAERS)的见解
背景:非传染性肺炎(NIP)是一种严重的药物不良反应。为了更好地了解药物性NIP,提高患者安全,并为临床决策提供信息,本研究旨在利用FDA不良事件报告系统(FAERS)数据库评估药物与NIP之间的关系,识别潜在的危险因素,并提供临床预警。研究设计和方法:我们回顾了2004年至2024年第二季度的FAERS数据库。以“NIP”为检索词,按仿制药名称和提交到FAERS数据库的与NIP相关的报告趋势对病例进行分类、统计和分析。我们采用了四种统计方法来鉴别与NIP相关的药物。结果:在21,433,114例报告的药物不良事件中,9224例被归类为NIP。我们的分析确定了20种与NIP相关的药物,主要类别是抗肿瘤药、抗生素和免疫抑制剂。达托霉素、甲氨蝶呤和他克莫司的nip相关死亡率最高。不良反应报告的趋势表明,NIP报告中增长最快的药物是达托霉素、甲氨蝶呤、舍曲林和胺碘酮。结论:这些发现有助于临床医生早期识别药物相关性NIP,并为进一步研究药物相关性NIP的机制提供有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信